Journal
Journal for ImmunoTherapy of Cancer
Publication Date
9-28-2024
Volume
12
Issue
9
First Page
e009472
Document Type
Open Access Publication
DOI
10.1136/jitc-2024-009472
Rights and Permissions
Seligson ND, Chen JL, Goodrich AC, Van Tine BA, Campbell JD, Richards AL, Antonescu CR, Liebner DA, Milhem MM, Streicher H, Tap WD, Schwartz GK, George S, D'Angelo SP. A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses. J Immunother Cancer. 2024 Sep 28;12(9):e009472. doi: 10.1136/jitc-2024-009472.© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Recommended Citation
Seligson, Nathan D; Chen, James L; Goodrich, Austin C; Van Tine, Brian A; Campbell, Jordan D; Richards, Allison L; Antonescu, Cristina R; Liebner, David A; Milhem, Mohammed M; Streicher, Howard; Tap, William D; Schwartz, Gary K; George, Suzanne; and D'Angelo, Sandra P, "A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): Expansion cohorts and correlative analyses." Journal for ImmunoTherapy of Cancer. 12, 9. e009472 (2024).
https://digitalcommons.wustl.edu/oa_4/4376
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
